Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study

BACKGROUND: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) after previous failed gemcitabine-based therapy. This population-based study aimed to evaluate the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Tai-Jan, Su, Yung-Yeh, Yang, Shih-Hung, Li, Chung-Pin, Bai, Li-Yuan, Chiang, Nai-Jung, Chuang, Shih-Chang, Shan, Yan-Shen, Chan, De-Chuan, Chen, Li-Tzong, Yen, Chia-Jui, Peng, Cheng-Ming, Chen, Yen-Yang, Chen, Jen-Shi, Chou, Wen-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606735/
https://www.ncbi.nlm.nih.gov/pubmed/34819998
http://dx.doi.org/10.1177/17588359211058255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606735/
https://www.ncbi.nlm.nih.gov/pubmed/34819998
http://dx.doi.org/10.1177/17588359211058255

Ejemplares similares